The results showed that myocardial glucose uptake ability decreased in 3 studies (11, 15, 41), while 2 studies (13, 44) demonstrated a significant increase in GLUT4 protein expression in the Empagliflozin group, regardless of T2DM. This evidence concerns the gene SLC2A4 and type 2 diabetes mellitus.